Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Jason Gotlib, John Mascarenhas, Raajit Rampal, Abdulraheem Yacoub, Hongfei Li, Josu Santamaria, Molly Halloran, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2025-2051

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Andrew Kuykendall, Rupali Roy, Abdulraheem Yacoub, Marina Kremyanskaya, Aaron Gerds, Ronald Paquette, Jeanne Palmer, Kathryn Johnson, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Ashley Yu, Rami Komrokji, Raajit Rampal, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 483.

https://doi.org/10.1182/blood-2025-483

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis

Moazzam Shahzad, Aqeeb Ur Rehman, Aroog Khaliq, Muhammad Kashif Amin, Jordan Leal, Olivia Molander, Philip Lubanski, Maggie Nelson, Abdulraheem Yacoub, Anurag Singh, Mehdi Hamadani, Joseph McGuirk, Muhammad Umair Mushtaq

Blood (2025) 146 (Supplement 1): 2460.

https://doi.org/10.1182/blood-2025-2460

Published: 2025

Journal Articles

Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study

Naveen Pemmaraju, Ellen Ritchie, John Mascarenhas, Salman Fazal, Erin Crowgey, TaeHyung (Simon) Kim, J.E. Hamer-Maansson, Tricia Kalafut, Evan Braunstein, Abdulraheem Yacoub

Blood (2025) 146 (Supplement 1): 5526.

https://doi.org/10.1182/blood-2025-5526

Published: 2025

Journal Articles

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

John Mascarenhas, Justin Johnson, Heidi Kosiorek, Megan Metzger, Tiziano Barbui, Josef Prchal, Alessandro Rambaldi, Abdulraheem Yacoub, Ashley Yu, Ruben Mesa, Marina Kremyanskaya, Amylou Dueck, Ronald Hoffman, Mohamed Salama

Blood (2025) 146 (Supplement 1): 5590.

https://doi.org/10.1182/blood-2025-5590

Published: 2025

Journal Articles

A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

John O. Mascarenhas, Uma Borate, Prithviraj Bose, John C. Byrd, Jacqueline S. Garcia, Michael R. Grunwald, Gabriela S. Hobbs, Ronald Hoffman, Andrew T. Kuykendall, Ruben A. Mesa, Stephen Oh, Raajit Rampal, Abdulraheem Yacoub, David P. Steensma

Blood (2024) 144 (Supplement 1): 3147.1.

https://doi.org/10.1182/blood-2024-193905

Published: 2024

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis

Moazzam Shahzad, Muhammad Kashif Amin, Ben Ponvilawan, Hana Qasim, Matthew McGuirk, Sibgha Gull Chaudhary, Iqra Anwar, Abat Khan, Abdulraheem Yacoub, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2024-193357

Published: 2024

Journal Articles

Comparative Effectiveness of Chatgpt 4.0 and Gemini Advanced in Diagnosing Challenging Hematologic Cases

Ibrahim Khamees, Xiangni Wu, Hana Qasim, Anas Al-sadi, Ma'in Abumuhfouz, Abdulraheem Yacoub, Haoran Li

Blood (2024) 144 (Supplement 1): 7501.

https://doi.org/10.1182/blood-2024-198703

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Moazzam Shahzad, Sohaib Irfan, Muhammad Kashif Amin, Muhammad Jawad Javed, Matthew McGuirk, Sibgha Gull Chaudhary, Iqra Anwar, Zobia Farooq, Abdulraheem Yacoub, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2024-193477

Published: 2024

Journal Articles

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, Praneeth Baratam, Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, Ben K. Tomlinson, Jay Yang, Pankit Vachhani, Joseph G Jurcic, Caspian H. Oliai, Jessica Liegel, Edward Pearson, Anna Van Rhenen, Marcello Rotta, Kapil Rathi, Juan Pinelli, Tara Chen, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2024-199634

Published: 2024

Journal Articles

Long Term Clinical and Molecular Responses in Patients with Polycythemia Vera and Essential Thrombocytosis Receiving Pegylated Interferon-Alpha Therapy

Leah Diebolt, Nicole Twardowski, Jayda Esplund, Jianzheng Wu, Dinesh Pal Mudaranthakam, Abdulraheem Yacoub

Blood (2024) 144 (Supplement 1): 6682.

https://doi.org/10.1182/blood-2024-201840

Published: 2024

Journal Articles

Systematic Approach to Treatment De-Escalation While Maintaining Remission in CML, a Risk Mitigation and Cost Reduction Study

Nicole Twardowski, Razan Mansour, Jianzheng Wu, Dinesh Pal Mudaranthakam, Leah Diebolt, Abdulraheem Yacoub

Blood (2024) 144 (Supplement 1): 6586.

https://doi.org/10.1182/blood-2024-198636

Published: 2024

Journal Articles

Pilot Phase II Trial of the Combination of Tagraxofusp with Pacritinib in Patients with Myelofibrosis, Tagpac Study

Abdulraheem Yacoub, Tara L. Lin, Heather J Male, Kenneth P Byrd, Haitham Abdelhakim, Lisa Stewart, Maddie Jensen, Jesus D Gonzalez Lugo

Blood (2024) 144 (Supplement 1): 6641.

https://doi.org/10.1182/blood-2024-194439

Published: 2024

Journal Articles

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Daniel Winokur, Brian Mulherin, Abdulraheem Yacoub, Soyon Lee, Ver Bilano, Glorian Yen, Anumaxine Geevarghese, Jincy Paulose, Annie Guerin, Dominick Latremouille-Viau, Rebecca Bungay, Gayatri Marathe, Anem Waheed

Blood (2024) 144 (Supplement 1): 7553.

https://doi.org/10.1182/blood-2024-199147

Published: 2024

Journal Articles

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Abdulraheem Yacoub, Ghaith Abu-Zeinah, Albert Qin, Weichung Joe Shih, Waleed Da'na, Tsewang Tashi, Oleh Zagrijtschuk, Robert Geller, Harinder Gill

Blood (2024) 144 (Supplement 1): 6626.

https://doi.org/10.1182/blood-2024-199337

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis using post-transplant cyclophosphamide-based gvhd prophylaxis

Identification of biomarkers to predict disease progression via molecular analysis of patients (pts) with low-risk myelofibrosis (MF) enrolled in the MOST study

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged over 70 Years with Myelofibrosis

Comparative Effectiveness of Chatgpt 4.0 and Gemini Advanced in Diagnosing Challenging Hematologic Cases

Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Long Term Clinical and Molecular Responses in Patients with Polycythemia Vera and Essential Thrombocytosis Receiving Pegylated Interferon-Alpha Therapy

Systematic Approach to Treatment De-Escalation While Maintaining Remission in CML, a Risk Mitigation and Cost Reduction Study

Pilot Phase II Trial of the Combination of Tagraxofusp with Pacritinib in Patients with Myelofibrosis, Tagpac Study

Intravenous Treatment Workflow for Paroxysmal Nocturnal Hemoglobinuria from the Perspective of Nurses and Pharmacists in US Clinical Practices

Paradigm-PV: A Global, Randomized, Multicenter, Two-Arm Phase IV Study to Assess the Efficacy and Safety of Ropeginterferon Alfa-2b in Low- and High-Risk Patients with Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only